Staphylococcus aureus 4-antigen vaccine
Phase 2Vaccine
PfizerStaphylococcus aureus 4-antigen vaccine is one of 38 biologic programs targeting Spinal Fusion. It is currently in Phase 2.
1
Indications
2
Total Trials
0
Active Trials
37
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
48 competitors in Spinal Fusion
#DrugCompanyPhaseTrials
1Medrol
PfizerApproved
MS Contin
HHikma Pharmaceuticals LLC
Approved
Ultiva
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Decadron
AAspen Global Incorporated
Approved
Marcaine
IInnocoll
Approved
Toradol
JJavelin Pharmaceuticals
Approved
Vancocin
HHikma Pharmaceuticals LLC
Approved
Vivarin
HHikma Pharmaceuticals LLC
Approved
Duragesic
CCephalon
Approved
Dilaudid
RRhodes Pharmaceuticals, L.P.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]